Purpose: To investigate dexamethasone intravitreal implant (DEX Implant 0.7 mg, Ozurdex; Allergan, Inc, Irvine, CA) as a treatment for persistent cystoid macular edema (CME) secondary to uveitis.
Methods: Treatment and outcomes data were collected retrospectively for 18 eyes from 13 consecutive patients treated with the DEX Implant for persistent, noninfectious uveitic CME. Outcome measures included the cumulative incidence of resolution of CME, visual acuity, central retinal thickness (measured by spectral domain optical coherence tomography), and vitreous haze score.
Results: After a single DEX Implant, there was no detectable CME in 89% and 72% of eyes at 1 month and 3 months, respectively. The median time to recurrence of CME (±standard error) was 201 ± 62 days. The percentage of eyes with no recurrence of CME was 35% at 6 months and 30% at 12 months. At 3 months, there was a significant improvement from baseline in mean visual acuity (+2.1 lines, P < 0.01). Eyes with an epiretinal membrane at baseline had shorter time to recurrence of CME and smaller improvements in visual acuity and central retinal thickness than eyes without an epiretinal membrane. At least 1 episode of intraocular pressure >25 mmHg occurred within the first 3 months in 11% (2 of 18) of eyes; all effectively managed with topical hypotensive medications.
Conclusion: A single DEX Implant produced sustained improvements in both visual acuity and retinal thickness in the majority of eyes with persistent uveitic CME. Uveitic CME did gradually recur in most eyes; however, close posttreatment monitoring is recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0000000000000515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibacterial and osteogenic gain strategy on titanium surfaces for preventing implant-related infections.
Colloids Surf B Biointerfaces
December 2024
College of Chemical Engineering, Xinjiang Normal University, 102 Xinyi Road, Urumqi 830054, P.R. China. Electronic address:
Infection and insufficient osseointegration are the primary factors leading to the failure of titanium-based implants. Surface coating modifications that combine both antibacterial and osteogenic properties are commonly employed strategies. However, the challenge of achieving rapid antibacterial action and consistent osteogenesis with these coatings remains unresolved.
View Article and Find Full Text PDFSafety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study.
Eye (Lond)
January 2025
Department of Ophthalmology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Purpose: To evaluate the efficacy and safety of dexamethasone implantation in the supraciliary (SC) space, a novel and potential effective implantation site, compared to intravitreal (IV) application.
Methods: This prospective study included 39 eyes of 38 patients with macular oedema (ME) who underwent SC and IV dexamethasone implantation (SC-DEX and IV-DEX). Patients were randomly assigned to treatment groups and followed for 3 months.
Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review.
Front Med (Lausanne)
November 2024
Department of Biomedicine, Neuroscience and Advanced Diagnostic, Eye Clinic, University of Palermo, Palermo, Italy.
Background/objective: Retinal vein occlusion (RVO) is a common, sight-threatening vascular disorder affecting individuals of all ages, with incidence increasing with age. Due to its complex, multifactorial nature, treating RVO remains a clinical challenge. Currently, treatment strategies include laser photocoagulation (especially for branch RVO), anti-VEGF therapies, and intravitreal corticosteroids.
View Article and Find Full Text PDFDexmedetomidine regulates the anti-oxidation and autophagy of adipose-derived stromal cells under HO-induced oxidative stress through Nrf2/p62 pathway and improves the retention rate of autologous fat transplantation.
Front Pharmacol
November 2024
Department of Plastic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
To investigate the protective mechanism of dexmedetomidine (DEX) on adipose-derived stromal cells (ADSCs) under oxidative stress model and its promotion effect on the retention rate of adipose granule transplantation by and experiments. The experiment was divided into control group, model group (ADSCs + HO+normal serum), DEX group (ADSCs + H0+DEX drug-containing serum), autophagy agonist group (ADSCs + HO+rapamycin (RAP)+normal serum), RAP + DEX group (ADSCs + HO+normal serum), RAP + DEX drug-containing serum), autophagy inhibitor group (ADSCs + HO+chloroquine (CQ)+normal serum), CQ + DEX group (ADSCs + HO+CQ + DEX drug-containing serum). HO-1, GSH-PX, SOD and CAT in ADSCs under oxidative stress model were measured.
View Article and Find Full Text PDFSelf-Extracting Dextran-Based Hydrogel Microneedle Arrays with an Interpenetrating Bioelectroenzymatic Sensor for Transdermal Monitoring with Matrix Protection.
Adv Healthc Mater
January 2025
Department of Molecular Chemistry, Univ. Grenoble Alpes-CNRS, 38041 Grenoble, France.
Continuous glucose monitors have revolutionized diabetes management, yet such devices are limited by their cost, invasiveness, and stability. Microneedle (MN) arrays could offer improved comfort compared to invasive implanted or mm-sized needle devices, but such arrays are hampered by complex fabrication processes, limited mechanical and sensor stability, and/or cytotoxicity concerns. This work demonstrates the first crosslinked hydrogel microneedle-bioelectroenzymatic sensor arrays capable of biomarker extraction and robust transdermal continuous monitoring in artificial interstitial fluid for 10 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!